Evidence map›Paper›PMID 41739311›Full record

ReviewDiscover oncology2026

Multimodal artificial intelligence for enhanced skin cancer diagnosis and prognosis.

Arun Karnwal, Manickam Selvaraj, Gaurav Kumar, Anupam Kumar, Abdel Rahman Mohammad Said Al-Tawaha, Aqueel-Ur-Rehman, Natalia Nesterova

Abstract readReview
In one paragraph

Review in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Arun KarnwalDepartment of Microbiology, Graphic Era (Deemed to be University), Dehradun, Uttarakhand, 248002, India. arunkarnwal@gmail.com.
Manickam SelvarajDepartment of Chemistry, Faculty of Science, King Khalid University, Abha, 61413, Saudi Arabia.
Gaurav KumarAmity Institute of Microbial Technology, Amity University Rajasthan, Jaipur, 303002, India.
Anupam KumarDepartment of Biotechnology, Faculty of Applied and Health Sciences, Parul University, Quepem, Goa, India.
Abdel Rahman Mohammad Said Al-TawahaDepartment of Biological Sciences, Al Hussein Bin Talal University Ma'an, Ma'an, Jordan.
Aqueel-Ur-RehmanDepartment of Biotechnology, Graphic Era (Deemed to be University), Dehradun, Uttarakhand, 248002, India.
Natalia NesterovaNational University of Life and Environmental Sciences of Ukraine, Kyiv, Ukraine. natalianesterova@nubip.edu.ua.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Skin cancer represents one of the most common and clinically significant malignancies worldwide, with rising incidence and substantial mortality, particularly melanoma, which accounts for approximately 75–80% of skin cancer-related deaths despite comprising < 5% of cases. Early detection and accurate prognostication remain essential for improving patient outcomes, yet subjectivity, resource constraints, and inter-observer variability often limit conventional diagnostic methods. Recent advances in artificial intelligence (AI), particularly deep learning, have demonstrated remarkable potential in enhancing diagnostic precision, risk stratification, and personalized treatment planning. Convolutional neural networks, vision transformers, and hybrid architectures have achieved dermatologist-level accuracy in classifying dermoscopic and clinical images, while multimodal approaches integrating histopathology, genomics, and patient metadata have improved prognostic assessments. Despite these advances, significant challenges remain, including dataset biases, lack of interpretability, regulatory barriers, and disparities in access to AI technologies. Addressing these challenges through explainable AI, federated learning, robust clinical validation, and equitable deployment strategies will be crucial for translation into routine practice. This review synthesizes current evidence on AI applications in skin cancer diagnosis and prognosis, highlights key technological innovations, and outlines the challenges and future directions necessary to ensure safe, effective, and globally accessible integration of AI into dermatological care.​.

Indexed as

Artificial intelligenceDeep learningDermatologyDiagnosisPrognosisSkin cancer

Identifiers

PMID41739311
PMCPMC13038710

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.